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Abstract:  Objective: Tissue inhibitors of metalloproteinases (TIMPs) are multi-functional proteins with matrix 
metalloproteinases-inhibiting activities. We studied expression of anti-inflammatory, TIMP-4 gene in human joint tissues 
and its regulation by arthritis-associated cytokines. 
Results: TIMP-4 RNA expression originating from synovial fibroblasts was significantly (2.4 fold; p<0.001) elevated in 8 
osteoarthritic (OA) versus 7 non-arthritic synovial membranes. Non-arthritic and OA femoral head and knee chondrocytes 
displayed substantial but variably constitutive expression of the TIMP-4 mRNA. In articular chondrocytes, transforming 
growth factor beta (TGF-1) and oncostatin M (OSM) upregulated TIMP-4 RNA and protein expression while 
interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-) did not, suggesting differential regulation by arthritis-
associated cytokines. Interleukin 17 (IL-17) mildly induced TIMP-4 mRNA. TGF-1 induction of TIMP-4 expression was 
partly inhibited by ERK pathway and Sp1 transcription factor inhibitors. 
Conclusion: Enhanced TIMP-4 gene expression in OA synovial membranes and cartilage may be due to induction by 
TGF-1, OSM and IL-17, suggesting its pathophysiological role in tissue remodeling in human joints. TGF-1 induction 
of TIMP-4 expression is mediated partly by ERK pathway and Sp1 transcription factor. 
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INTRODUCTION 
  The TIMP gene family consists of four members, which 
have matrix metalloproteinases (MMPs)-inhibiting, anti-
angiogenic, growth-promoting and proapoptotic activities in 
diverse systems [1]. TIMP-4 inhibits endothelial cell mig-
ration but does not block angiogenesis and may have distinct 
properties [2]. Abilities of TIMPs (particularly TIMP-3) to 
inhibit MMPs, ADAMTS-4/5 (aggrecanases) and tumor 
necrosis factor (TNF-) converting enzyme (TACE/ADAM-
17) can potentially reduce joint inflammation and cartilage 
resorption in arthritis [3].
  TIMP-3 and TIMP-1 over-
expressing synovial fibroblasts have reduced capacity to 
invade cartilage in SCID mouse model [4]. TIMP-4 is 
expressed in human heart and certain other tissues [5].
 
TIMP-4 inhibits major MMPs including MMP-13 implicated 
in arthritic tissue damage [6]. TIMP-4 associates with MMP-
2/MT1-MMP complex but its knockout had no effect on 
MMP-2 activation [7]. Since TIMPs-MMPs/ADAMTS 
balance is critical for cartilage integrity, understanding the 
patterns of TIMP family expression and regulation in joints 
is of profound importance. MMP-3, TIMP-1 and TIMP-3 
mRNA is increased in human OA synovium and articular 
chondrocytes express TIMP-1, TIMP-2 and TIMP-3 genes  
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[8]. TIMP-4 gene therapy diminished experimental arthritis 
and periodontitis in rats, suggesting an association between 
the two inflammatory diseases and therapeutic potential of 
TIMP-4 [9, 10].
  Besides reported lack of expression in 
synovial fibroblasts [11], information about the TIMP-4 
expression in human joints is scant. We previously showed 
an increased TIMP-4 expression in femoral head cartilage of 
OA patients as a possible remodeling response, however, 
stimulating factors are unknown [12]. Synovial membrane is 
an important protective tissue around cartilage, which could 
become inflamed and hyperplasic during rheumatoid arthritis 
and could invade cartilage, leading to its destruction [13, 14]. 
Here we investigated whether TIMP-4 RNA is expressed in 
human non-arthritic and OA synovial membranes and if its 
expression is regulated by arthritis-related cytokines in 
chondrocytes. 
MATERIALS AND METHODS 
Patients, Tissues and Cell Culture 
   Synovial membranes from 7 non-arthritic, post-mortem 
(3 female and 4 male, mean age 53.6 years) tissues with no 
knee joint disease were analyzed. Knee OA synovial 
membranes were from eight patients (4 female and 4 male, 
mean age 71.3 years) with clinically and radiologically 
defined knee OA and were obtained after total knee 
replacement surgery. For TIMP-4 gene expression in human 
knee (patient data not available) and femoral head cartilage 
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hip late-stage OA, 9 female and 6 male, mean age 72.1 
years; osteophytes excluded), chondrocytes were released 
after digestion with pronase (1mg/ml) for 1 h followed by 
collagenase (2 mg/ml, Sigma type-II) for 8 h at 37
oC with 
agitation, grown for one week in DMEM supplemented with 
1X penicillin-streptomycin solution and 10% fetal calf serum 
as primary cultures, maintained in the same medium without 
serum for 24 h and RNA extracted. Synovial fibroblasts were 
obtained by mincing and digestion of non-OA or OA 
synovial membranes with 0.25% trypsin and 2 mg/ml 
collagenase, passing through strainer, culturing adherent 
cells and removal of non-adherent cells. Synovial fibroblasts 
at passage 3 were kept in 0.5% serum for 24 h before RNA 
extraction. For cytokine treatments, high-density passage 2 
knee chondrocytes (Cambrex) were grown to confluence, 
kept in serum-free medium for 36 h and treated with TGF-1 
(10 ng/ml), OSM (25 ng/ml), TNF- (20 ng/ml), IL-1 (10 
ng/ml) and IL-17 (20 ng/ml) (all from R&D Systems) for 24 
h and RNA and protein extracted. In some cases, 
chondrocytes in serum-free medium were pretreated with 
MEK inhibitor, U0126 (Calbiochem) or Sp1 inhibitor, 
mithramycin (Sigma-Aldrich) for 30 min and then induced 
with TGF-1 for 24 h and total RNA analyzed for TIMP-4 
and GAPDH expression by RT-PCR. The tissues used in this 
study were obtained either during autopsy (after 12 h of 
death due to cardiocerebral events) or during knee/hip 
replacement surgery at Hopital Notre-Dame du CHUM with 
the consent of patients or families and with the approval of 
Comité d’éthique de la recherche du Centre hospitalier de 
l’université de Montréal (CHUM) protocole number 
ND98.58 entitled “Base moléculaire de regulation des genes 
d’inhibiteurs tissulaire des métalloprotéinases-3 (TIMP-3) et 
(TIMP-4) par les facteures de croissance et antioxydants 
dans les cellules de tissues conjonctifs”. The research project 
conformed to the Helsinki declaration and local ethics 
committee regulations. 
RNA Extraction and RT-PCR 
  RNA from human knee synovial membranes was 
extracted by homogenization in guanidinium isothiocyanate 
solution and cesium chloride ultracentrifugation, quantified 
and its integrity verified by gel electrophoresis as described 
[8]. Total RNA from primary cultures was isolated by the 
acid guanidinium thiocyanate-phenol-chloroform method 
[15]. 
  For RT-PCR, 2 μg RNA was heated for 5 min at 65
oC 
and reverse transcribed in the reaction mixture consisting of 
oligo d (T) 12-18mer, dNTPs, RNase inhibitor (Amersham-
Pharmacia), acetylated BSA with reverse transcriptase 
(MMLV-RT) (Invitrogen) according to Clontech (Paolo 
Alto, CA) protocols. Aliquots of 5 μl were subjected to PCR 
with TIMP-4 or GAPDH primers. The forward and reverse 
primers specific for human TIMP-4 cDNA [5] were: 5'-AGA 
CCT CAC AGG CTC AGT CG-3' and 5'-CAT TCC TGC 
CAG TCA GCC TG-3' respectively. The amplification 
profile was one cycle of 94
oC for one min (hot start), 35 
cycles of 94
oC for one min, hybridization at 60
oC for 2 min 
and extension at 72
oC for 3 min. A final extension cycle of 7 
min at 72
oC was also included. The amplifications were 
performed in the GeneE cycler (Techne, England) in a 50 μl  
 
reaction with 1.25 mM dNTPs, Taq DNA polymerase 
(Pharmacia) and respective primers. The GAPDH cDNA 
amplification kit and primers were from Maxime Biotech. 
Inc. (South San Francisco, CA). Aliquots (10 μl) were 
analyzed on 1.2 (TIMP-4) or 1.4 (GAPDH) % agarose gels 
to detect TIMP-4 and GAPDH amplicons of 1148 and 226 
bp respectively. Negative controls included either RT-PCR 
reagents except cDNA or, RT minus reactions. None of them 
gave any bands. The TIMP-4 cDNA was cloned in pGEM-
4Z and its identity confirmed by comparison with the 
reported DNA sequence [5].
 
  TIMP-4 cDNA band intensities were quantified by NIH 
ImageJ 1.32j (National Institute of Health, USA) software 
and divided by those of GAPDH. Results are reported as 
means ± SEM of at least 3 different experiments and were 
compared with Prism software by student’s t test or 
ANOVA, followed by a Newman-Keuls multiple comparison. p 
< 0.05 was considered significant.
 
Western Blotting 
  Total cellular proteins (20 μg/lane) were separated by 
SDS-PAGE and blots reacted with rabbit Anti-carboxy 
terminus human TIMP-4 polyclonal antibody (Chemicon 
AB816) that detects a ~29-kDa band, which co-migrates 
with the purified human TIMP-4 protein. 
RESULTS 
TIMP-4 Expression in Human Synovial Membranes 
  Ability of human synovium to express the newest TIMP-
4 gene was investigated. RT-PCR analysis of RNA from 7 
control and 8 knee OA patients revealed that both categories 
of subjects expressed TIMP-4 mRNA. One normal and one 
OA synovium had lower but detectable levels of TIMP-4 
mRNA relative to the other samples. Cloning and DNA 
sequencing of the PCR product at both ends confirmed its 
identity as TIMP-4 cDNA. The control GAPDH mRNA 
levels remained consistent (Fig. 1A). Quantitative analysis of 
the bands revealed a statistically significant (p<0.001) 2.4 
fold enhancement of TIMP-4 expression in OA patients (Fig. 
1B). TIMP-4 expression in the tissues originated partly from 
synovial fibroblasts as 5 separate synovial fibroblast cell 
lines expressed TIMP-4 mRNA (Fig. 1C). 
TIMP-4 Expression in Human Hip and Knee 
Chondrocytes 
  To examine if human hip joint chondrocytes expressed 
TIMP-4 gene ex vivo, RNAs from the quiescent 
chondrocytes of two older patients with femoral fracture and 
15 patients with hip OA were analyzed. All specimens 
expressed variable but clearly detectable levels of TIMP-4 
mRNA along with consistent GAPDH control mRNAs. 
Determination of TIMP-4/GAPDH ratio revealed an 
increased tendency of TIMP-4 expression (though not 
statistically significant) in hip OA chondrocytes (Fig. 2A). 
Chondrocytes from 6 normal human knees also expressed 
TIMP-4 RNA but its expression in OA chondrocytes was 
variable Nevertheless, calculation of TIMP-4/GAPDH ratio 
revealed a decreased tendency (not statistically significant) 
of TIMP-4 expression in knee OA chondrocytes (Fig. 2B). Enhanced Expression of Tissue Inhibitor of Metalloproteinases-4 Gene  The Open Rheumatology Journal, 2011, Volume 5   83 
Impact of Cytokines on TIMP-4 Expression in Human 
Chondrocytes 
  To identify the possible stimuli responsible for TIMP-4 
increase in joints (this work and [12]), we investigated the 
previously unreported TIMP-4 regulation by the cytokines 
and growth factors found elevated in arthritic joints [16]. 
Treatment of normal human knee chondrocytes with TGF-
1, OSM, TNF-, IL-1 and IL-17 (at doses known to 
induce MMPs or other TIMPs) for 24 h revealed that TGF-
 
Fig. (1). A) Expression of the TIMP-4 gene in human synovial membranes from non-arthritic and osteoarthritic patients. The specific 
amplification of TIMP-4 and GAPDH fragments (arrows) along with the lambda Hind III or 100 bp ladder markers is shown. ‘No DNA’ 
control lane represents PCR reactions with primers but without cDNA. B) Middle panels show two graphic representations of semi-
quantitative analysis of TIMP-4 RNA bands. *** p<0.001 Non-osteoarthritic (non-OA) versus osteoarthritic (OA). C) TIMP-4 RNA is 
expressed in non-OA (lane 1, 4, 5) and OA (lane 2, 3) synovial fibroblast lines from different patients. 84   The Open Rheumatology Journal, 2011, Volume 5  Huang et al. 
1, OSM and IL-17 moderately (0.5-1 fold) up-regulated 
while IL-1 and TNF- did not induce TIMP-4 RNA. A 
similar pattern of induction was observed at the protein level 
(Fig. 3). 
Mechanism of TIMP-4 Induction by TGF-1 
 Since  TGF-1 induces TIMP-3 gene regulation through 
activation of extracellular-signal-regulated kinase (ERK) 
pathway and Sp1 [17], we investigated whether TIMP-4 is 
regulated by such a mechanism. TGF-1 induced TIMP-4 
mRNA and MEK inhibitor, U0126 treatment, partially 
suppressed this induction (Fig. 4A, left panel). Similar 
inhibition by U016 was observed when TIMP-4/GAPDH 
ratios from three independent experiments were determined 
(Fig.  4A, right panel). Similarly, Sp1 transcription factor 
inhibitor, mithramycin almost completely suppressed TIMP-
4 induction (Fig. 4B, left panel). Determination of TIMP-
4/GAPDH ratios from two independent experiments revealed 
TIMP-4 inhibition by mithramycin (Fig. 4B, left panel). 
Although statistically non-significant, these results suggest 
that ERK pathway and Sp1 factor are important mediators of 
TIMP-4 induction by TGF-1. 
DISCUSSION 
  Increase in TIMP-4 mRNA levels in OA synovial 
membranes suggests a pattern analogous to that of TIMP-1 
and TIMP-3, which may possibly be to counteract excessive 
MMP-driven destruction [8]. Indeed, MMP-1, MMP-3 and 
MMP-13 are increased in pannus-like tissue in advanced OA 
[18]. Furthermore, synovitis has been observed in knees of 
patients with OA [19]. TIMP-4 increase by gene therapy is 
known to reduce levels of proinflammatory cytokines, IL-1 and 
TNF- [9]. Previously reported lack of TIMP-4 expression in 
immortalized synovial fibroblasts [11] may be due to lower 
sensitivity of RNAse protection assay compared to the more 
sensitive RT-PCR technique used here. Our results clearly 
demonstrate synovial fibroblast as one of the cell-types that 
contributes to the observed expression in the tissue. It is 
possible that inflammatory cells in joints also express TIMP-
4 as observed in atherosclerotic tissue inflammation [20]. 
 
Fig. (2). A) Expression of the TIMP-4 mRNA in primary human non-arthritic and OA femoral head articular chondrocytes. All conditions 
were same as in Figure 1. The right panel is a cumulative graphic depiction of mean ± SEM TIMP-4/GAPDH ratios indicating TIMP-4 
increase in hip OA chondrocytes. B) TIMP-4 RNA expression by RT-PCR analysis in knee chondrocytes from six non-OA and 6 OA 
patients with negative control (no DNA) and markers. The right panel is a cumulative graphic depiction of mean ± SEM TIMP-4/GAPDH 
ratios indicating TIMP-4 decrease in knee OA chondrocytes. Enhanced Expression of Tissue Inhibitor of Metalloproteinases-4 Gene  The Open Rheumatology Journal, 2011, Volume 5   85 
Constitutive TIMP-4 expression levels in non-OA synovial 
tissues may be related to its important role and persistent 
requirement in physiologic situations such as protection of 
synovial ECM integrity, anti-angiogenic, growth-promoting 
or anti-apoptotic activities [1]. TIMP-4 gene delivery is 
known to stimulate growth of breast cancer cells [21]. 
  Human femoral head normal and OA chondrocytes clearly 
synthesize TIMP-4 mRNA under ex vivo conditions suggesting 
its physiological roles in maintenance of balance with MMPs 
to protect its matrix. These results represent mainly older 
patients as tissues from young patients were not available. 
The reasons for its constitutive expression in normal and 
variable expression in knee OA chondrocytes are unknown. 
Some OA patients may have decreased expression of TIMP-
4 as reported for the end-stage hip OA cartilage [22]. 
Whether TIMP-4 deficiency contributes to OA pathogenesis, 
remains to be studied further. In one report, TIMP-4 RNA 
reduction in periprosthetic interface tissue has been associated 
with loose artificial hip prosthesis [23]. In contrast with the 
increased TIMP-1, TIMP-2 and TIMP-3, TIMP-4 RNA levels 
 
Fig. (3). Impact of TGF-1, OSM, TNF-, IL-1 and IL-17 on TIMP-4 RNA expression in normal human knee primary chondrocytes kept 
in serum-deficient medium for 24 h, subjected to the indicated treatments and RNA levels analyzed by TIMP-4 and GAPDH RT-PCR. The 
results are cumulative representative of three independent experiments. On the bottom panel, quantitative analysis of TIMP-4 versus GAPDH 
RNA is shown: p < 0.01 Control versus TGF- and IL-17; ** p < 0.05 Control versus OSM*. Whiskers in the graph represent means ± SEM. 
TIMP-4 protein levels (except IL-17, not determined) measured by Western blot analysis are also shown. 86   The Open Rheumatology Journal, 2011, Volume 5  Huang et al. 
were decreased during early inflammatory phase of healing 
rabbit ligaments [24]. Single nucleotide polymorphism at the 
3’-untranslanted region of TIMP-4 gene has also been 
associated with susceptibility of Korean patients to OA [25]. 
  Arthritis-associated cytokines differentially regulate TIMP-
4 gene expression in knee chondrocytes. Induction of TIMP-4 
by TGF-1, a major stimulant of cartilage matrix synthesis 
and an antiapoptotic factor in synovial fibroblasts [26] 
suggests its role in cartilage remodeling and repair as 
observed during OA pathogenesis. TGF-1 and OSM are 
also known to upregulate TIMP-1 and TIMP-3 in 
chondrocytes [17, 27] and could be responsible for the 
observed TIMP-4 increase in vivo. The overall mild cytokine 
effect in normal chondrocytes may be due to constitutive and 
elevated basal TIMP-4 mRNA expression. 
 
Fig. (4). Down-regulation of TGF-1-induced TIMP-4 RNA expression by (A) ERK (U0126) and (B) Sp1 (mithramycin) inhibitors as 
analyzed by RT-PCR. Human knee chondrocytes were kept in serum-deficient medium for 24 h, subjected to the indicated treatments for 24 
h and mRNA levels analyzed by TIMP-4 and GAPDH RT-PCR. The right panels are cumulative graphic depictions of mean TIMP-
4/GAPDH ratios of three (A) or two (B) separate experiments. Enhanced Expression of Tissue Inhibitor of Metalloproteinases-4 Gene  The Open Rheumatology Journal, 2011, Volume 5   87 
  In summary, previously undocumented increase of 
TIMP-4 in human knee synovium and expression in primary 
hip and knee chondrocytes was demonstrated. TIMP-4 was 
differentially induced by arthritis-associated cytokines. In 
vivo increase may be due to its induction by TGF-1, OSM 
and IL-17. TGF-1 induces TIMP-4 gene expression partly 
through ERK and Sp1 pathways. Due to multiple activities 
of TIMPs in other tissues, additional studies are needed to 
define TIMP-4 regulation and functions in joints and its 
potential for inhibiting cartilage and bone resorption [28]. 
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